Although the mechanism through which these small-molecule inhibitors affect cancer immunotherapy remains unclear, the loss of HIF-1α adversely affects CD8+ T-cell infiltration, resulting in the loss of antitumor activity in cancer immunotherapy models and finally leading to accelerated tumor growth [214]. The gene discussed is CD8A; the disease is cancer.